Treatment of vulvar lichen sclerosus with topical corticosteroids in children: a study of 72 children

• Published in: Clinical and experimental dermatology Vol. 40; no. 3; pp. 289 - 292
• Main Authors: Casey, G. A., Cooper, S. M., Powell, J. J.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01-04-2015; Oxford University Press
• Subjects: Administration, Topical; Adolescent; Child; Child, Preschool; Clobetasol - administration & dosage; Dermatologic Agents - administration & dosage; Female; Glucocorticoids - administration & dosage; Humans; Male; Prospective Studies; Vulvar Lichen Sclerosus - drug therapy
• ISSN: 0307-6938; 1365-2230
• DOI: 10.1111/ced.12519

Summary
Treatment of vulvar lichen sclerosus (VLS) in children by topical corticosteroids gives control of symptoms and some resolution of physical signs, but large studies are limited. We report the largest study of 72 prepubertal girls with VLS, 62 of whom were prospectively treated with daily application of an ultrapotent topical corticosteroid (UPTC), clobetasol propionate 0.05% ointment, for 3 months, with a follow‐up period of 4–8 years [the remaining 10 patients responded to mild to moderate potency topical corticosteroids (MPTCs)]. The results were compared with a retrospective study of 31 prepubertal girls with VLS treated with MPTCs. MPTCs led to symptom clearance in 32.2% of patients, whereas UPTC led to symptom clearance in 72.6% of patients. Improvement in clinical signs following UPTC occurred in 90.3% of children at 3 months, with total resolution of clinical signs occurring in 29.2% at the 4‐year follow‐up or at puberty. No serious adverse effects occurred with UPTC treatment. In children with VLS, UPTCs relieve symptoms, resolve signs and possibly prevent scarring. UPTCs should therefore be the treatment of choice for VLS in children.